

Charity Registration No. 1092386

**NEUROENDOCRINE CANCER UK**  
**PREVIOUSLY NET PATIENT FOUNDATION**  
**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
LEGAL AND ADMINISTRATIVE INFORMATION**

---

<b>Trustees</b>	Mr P Gwilliam (Chairman) Mrs R Littlejohn Dr R Srirajaskanthan Mrs I Wotherspoon Mr John Kent  Mr Tom Jackson	(Appointed 1 December 2021) (Appointed 7 June 2021)
<b>Charity number</b>	1092386	
<b>Principal address</b>	Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL	
<b>Independent examiner</b>	Chapman Worth Limited 3 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY	
<b>Bankers</b>	Lloyds Bank Butler Place Branch PO Box 100 BX1 1LT	

---

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
CONTENTS**

---

	<b>Page</b>
Trustees' report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Statement of financial position	7
Notes to the financial statements	8 - 20

---

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT**

**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

The Trustees have the pleasure in presenting the Trustees' Report and Accounts of Neuroendocrine Cancer UK for the year ended 30 September 2021. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016).

## **Objectives**

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are, (i) equality of care for all Neuroendocrine Cancer patients in the UK, (ii) excellence in support, care, treatment, and research, (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types, (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

## **Terminology, Purpose and Need**

The umbrella name for Neuroendocrine Cancers was changed by the World Health Organisation in 2017 to neuroendocrine neoplasms (NENs), incorporating tumours and neuroendocrine carcinomas. NENs are a group of unusual and unpredictable tumours which develop from cells in the diffuse endocrine system. NENs can affect people of any age and can be benign (non-cancerous) or malignant (cancerous). Neuroendocrine Cancer UK supports patients with malignant NENs (neuroendocrine cancer) which mostly arise in the lung or gastrointestinal system (but can occur in many organs of the body). Every year about 5,000 people are diagnosed with NENs in the UK with around 40,000 living with the disease. Incidence has increased from 4.6 per 100,000 to 8.7 per 100,000 recorded in 2016.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, sadness, and anxiety. For NEN patients specifically the prospect of a cure is often nil and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease meaning their cancer pathway begins with feelings of extreme frustration.

The results of our Barriers to Diagnosis Survey highlighted that more than half of our respondents were referred for further investigations or secondary care review by their GP, 20% presented through A&E and 20% were referred on by hospital doctors they were seeing for another condition. If referred by a hospital doctor - specialist team referral rose to 8%. 52% of respondents receive a diagnosis of Neuroendocrine Cancer following first referral to secondary (or tertiary) care. Of those who did not receive a diagnosis at this time - a third returned to their GP - with 29% visiting a further 1-2 times before being diagnosed, 17% visiting 3-5 times, 7.5% visiting 6-8 times, 5% visiting 8-10 times and 16% visiting more than 10 times before obtaining an accurate diagnosis.

For those who continued through secondary care - 40% had 1-2 visits before receiving a diagnosis of NC, 32% visited 3-5 times, however >28% required more than 6 further visits (12% more than 10).

# NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

*FOR THE YEAR ENDED 30 SEPTEMBER 2021*

---

Following a referral, treatment is often the next stage, and this requires patients to address the gravity of their diagnosis at home and often without regular access to the support of doctors and nurses. Therefore, patients frequently suffer from feelings of abandonment and struggle to know who to confide in. Indeed, if their cancer is particularly advanced, they face the possibility of dying. From our experience the complexity of NENs means that patients, family, and friends often struggle to comprehend their suffering. Our Psychotherapy service saw an increase in demand and our budget for this service represented that increase with a doubling of funds. Despite this increase in funds, demand led to a cease in service provision through Nov/Dec to catch up with the backlog.

People with a less common cancer like NENs are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experiences and to take positive and meaningful steps to address them.

## **Achievements and performance**

The CEO is supported by a full-time specialist nurse and a team of administrative and communications staff. A dedicated group of patient ambassadors also support the work of the organization and further ambassadors were added to the team this year totalling 12 to date.

Our services continue to be developed and grown, and key achievements are listed below:

- Launch of the Bridging the Gap Campaign - <https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer-uk-launches-bridging-the-gap-campaign/>
- NCRAS project development improving our understanding around the incidence and prevalence of disease, routes to diagnosis, secondary cancers and health economics surrounding a NEN diagnosis
- Two publications into international journals covering patient perspectives from diagnosis, through treatments and beyond, and the role of patient support groups in NENs.
- Publication of Barriers to Diagnosis survey
- Complete revision of patient factsheets with additional informational resources
- Development of the 'NETInfo' factsheets for the international community
- Presentations at national and international meetings
- Our CEO continuing her work as President of the International Neuroendocrine Cancer Alliance.
- Development of online Natters groups and 167 meetings held in the financial year
- Launch of the NCUK Nurse Academy - <https://ncukacademy.org.uk/>
- Policy work expanded through the NHS charities forum and work with Cancer 52

## **Note from the CEO Cathy Bouvier**

NCUK has been a formal entity since 2001 and so this year marks its 20th anniversary. There have been many changes and adaptations as we have matured and grown, but the ethos of the organisation has remained firm, and the voice of our community is key to our strategic plans. Towards the latter part of this financial year work has started on looking at the next 3-5 years, where we are, where we want to be and what we need to do to get there. We need to ensure that we have the right staff in both quantity and quality, to drive some important and challenging projects forward.

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)**

**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

## **Financial review**

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £214,538 for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £677,532 and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. This level of reserves is in line with the reserves policy of the charity and ensures that it can prepare these accounts on a going concern basis with sufficient contingency if the level of grants and donations should fall during a period of increased economic uncertainty.

## **Structure, governance and management**

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Trustees who served during the year and up to the date of signature of the financial statements were:

---

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
TRUSTEES' REPORT (CONTINUED)**


**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

Mr P Gwilliam (Chairman)	
Mr D Jones	(Resigned 25 February 2022)
Mrs M Phillips	(Resigned 12 October 2021)
Mrs R Littlejohn	
Dr R Srirajaskanthan	
Mrs I Wotherspoon	
Mr John Kent	(Appointed 1 December 2021)
Mr Tom Jackson	(Appointed 7 June 2021)

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.

  
.....  
**Mr P Gwilliam (Chairman)**  
Trustee  
Dated: 26/5/22

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
INDEPENDENT EXAMINER'S REPORT  
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

---

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2021.

**Responsibilities and basis of report**

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA  
Chapman Worth Limited  
3 The Old Estate Yard  
High Street  
East Hendred  
Wantage  
Oxfordshire  
OX12 8JY

Dated: .....

6 July 2022



**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
STATEMENT OF FINANCIAL ACTIVITIES  
INCLUDING INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
<b><u>Income from:</u></b>					
Donations and legacies	3	541,146	-	541,146	223,684
Grants	4	-	34,410	34,410	71,120
Investments	5	13	-	13	170
<b>Total income</b>		<u>541,159</u>	<u>34,410</u>	<u>575,569</u>	<u>294,974</u>
<b><u>Expenditure on:</u></b>					
Raising funds	6	8,021	-	8,021	4,958
Charitable activities	7	252,017	100,993	353,010	282,340
<b>Total resources expended</b>		<u>260,038</u>	<u>100,993</u>	<u>361,031</u>	<u>287,298</u>
<b>Net income/(expenditure) for the year/ Net movement in funds</b>		281,121	(66,583)	214,538	7,676
Fund balances at 1 October 2020		379,351	83,643	462,994	465,411
<b>Fund balances at 30 September 2021</b>		<u><u>660,472</u></u>	<u><u>17,060</u></u>	<u><u>677,532</u></u>	<u><u>473,087</u></u>

The statement of financial activities includes all gains and losses recognised in the year.


All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
STATEMENT OF FINANCIAL POSITION**

**AS AT 30 SEPTEMBER 2021**

	Notes	2021 £	£	2020 £	£
<b>Current assets</b>					
Debtors	13	2,866		2,461	
Cash at bank and in hand		678,355		476,485	
		<u>681,221</u>		<u>478,946</u>	
<b>Creditors: amounts falling due within one year</b>	14	<u>(3,689)</u>		<u>(5,859)</u>	
Net current assets			<u>677,532</u>		<u>473,087</u>
<b>Income funds</b>					
Restricted funds	16		17,060		83,643
Unrestricted funds - general			660,472		389,444
			<u>677,532</u>		<u>473,087</u>

The financial statements were approved by the Trustees on 26/5/22

  
.....  
Mr P Gwilliam (Chairman)  
Trustee

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**1 Accounting policies**

**Charity information**

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

**1.1 Accounting convention**

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**1.2 Going concern**

The trustees have assessed the implications of the ongoing pandemic on the charity's ability to continue for the foreseeable future and believe that the charity has adequate reserves to meet costs where there is a reduction in income for a significant period in the future. Income for the first quarter of the current year is running at a level that substantiates this assessment.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

**1.4 Income**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**1 Accounting policies**

**(Continued)**

**1.5 Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

**1.6 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.7 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

***Basic financial assets***

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**1 Accounting policies**

(Continued)

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

**1.8 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

**1.9 Retirement benefits**

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

**Critical judgements**

**Allocation of support costs**

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**3 Donations and legacies**

	<b>Unrestricted funds general 2021 £</b>	<b>Total 2020 £</b>
Donations and gifts	437,771	211,324
Legacies receivable	103,375	12,360
	<u>541,146</u>	<u>223,684</u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

4 Grants	Ipsen 2021 £	AAA 2021 £	Lottery 2021 £	Total 2021 £	Ipsen 2020 £	AAA 2020 £	Lottery 2020 £	ITM 2020 £	Total 2020 £
Performance related grants	14,000	16,858	3,552	34,410	9,800	43,827	7,500	9,993	71,120

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**5 Investments**

	<b>Unrestricted funds general 2021 £</b>	<b>Total 2020 £</b>
Interest receivable	13	170
	<u>13</u>	<u>170</u>

**6 Raising funds**

	<b>Unrestricted funds general 2021 £</b>	<b>Total 2020 £</b>
<u>Fundraising and publicity</u>		
Other fundraising costs	8,021	4,958
	<u>8,021</u>	<u>4,958</u>



**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

**7 Charitable activities**

	2021 £	2020 £
Staff costs	88,802	85,359
Charitable activities	100,548	62,208
Computer costs	2,192	1,973
Advertising and marketing	11,263	7,155
Travel and subsistence	1,777	5,055
Rent	9,127	9,057
Telephone	3,256	3,693
Office expenses	8,579	11,171
Legal and professional	2,438	3,300
Other costs	3,496	2,844
	<u>231,478</u>	<u>191,815</u>
Grant funding of activities (see note 9)	25,600	-
Share of support costs (see note 10)	91,839	84,914
Share of governance costs (see note 10)	4,093	5,611
	<u>353,010</u>	<u>282,340</u>
<b>Analysis by fund</b>		
Unrestricted funds - general	252,017	253,882
Restricted funds	100,993	28,458
	<u>353,010</u>	<u>282,340</u>

**8 Description of charitable activities**

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**9 Grants payable**

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
Kings College Hospital	25,000	-
Royal College of Nursing	600	-
	<u>25,600</u>	<u>-</u>
	<u><u>25,600</u></u>	<u><u>-</u></u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

10 Support costs	Support Governance costs		2021		Support Governance costs		2020		Basis of allocation	
	£	£	£	£	£	£	£	£		
Staff costs	76,328	-	76,328	69,203	-	69,203	Administrative staff	69,203		
Office expenses	2,145	-	2,145	2,793	-	2,793	20% of the cost (2020 20%)	2,793		
Legal and professional	609	-	609	825	-	825	20% of the cost (2020 20%)	825		
Computer costs	6,576	-	6,576	5,917	-	5,917	75% of the cost (2020 75%)	5,917		
Rent and rates	3,912	-	3,912	3,882	-	3,882	30% of the cost (2020 30%)	3,882		
Telecommunications	1,395	-	1,395	1,583	-	1,583	30% of the cost (2020 30%)	1,583		
Other costs	874	-	874	711	-	711	20% of the cost (2020 20%)	711		
Audit fees	-	4,093	4,093	-	4,228	4,228	Governance	4,228		
Trustees expenses	-	-	-	-	1,383	1,383	Governance	1,383		
	<u>91,839</u>	<u>4,093</u>	<u>95,932</u>	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>				
Analysed between										
Charitable activities	<u>91,839</u>	<u>4,093</u>	<u>95,932</u>	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>				

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the Independent Examiner of £1,872 (2020- £1,872) for the Independent Examination.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

**11 Trustees**

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year. One of the trustees received a payment of £850 for acting as an NCUK Academy speaker.

During the year Trustees donated a total of £240 (2020 - £240) to general funds.

**12 Employees**

The average monthly number of employees during the year was:

	<b>2021</b>	<b>2020</b>
	<b>Number</b>	<b>Number</b>
	6	5
	<u>6</u>	<u>5</u>
<b>Employment costs</b>	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
Wages and salaries	149,950	141,337
Social security costs	11,552	9,970
Other pension costs	3,628	3,255
	<u>165,130</u>	<u>154,562</u>

There were no employees whose annual remuneration was more than £60,000.

**13 Debtors**

	<b>2021</b>	<b>2020</b>
<b>Amounts falling due within one year:</b>	<b>£</b>	<b>£</b>
Other debtors	2,866	2,461
	<u>2,866</u>	<u>2,461</u>

**14 Creditors: amounts falling due within one year**

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
Other taxation and social security	834	2,482
Other creditors	983	1,505
Accruals and deferred income	1,872	1,872
	<u>3,689</u>	<u>5,859</u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

---

**15 Retirement benefit schemes**

**Defined contribution schemes**

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £3,627 (2020:£3,255).

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

**16 Restricted funds**

The Income Funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at October 2020	Movement in funds		Balance at 30 September 2021
		Incoming resources	Resources expended	
	£	£	£	£
IEL - App Project	15,181	-	(10,800)	4,381
Ipsen - Publicity/PR	3,335	-	(404)	2,931
AAA - Data Extraction / Medical Writing Project	14,000	-	(11,264)	2,736
AAA - NCUK Summit	8,500	-	(3,284)	5,216
AAA - Nurse Course	9,800	-	(9,800)	-
AAA - Patient Travel / Welfare Support	5,000	-	(3,204)	1,796
AAA - Psychological Support	6,527	-	(6,527)	-
Ipsen -Nurse Course	9,800	-	(9,800)	-
ITM - Mind the Gap Project	4,000	-	(4,000)	-
Lottery - Psychological Support	7,500	-	(7,500)	-
Ipsen - GP Course	-	14,000	(14,000)	-
Ipsen - Patient information Fact Sheets	-	1,776	(1,776)	-
AAA - GP Course	-	15,776	(15,776)	-
AAA - Patient information Fact Sheets	-	1,776	(1,776)	-
AAA - Royal College of Nursing Accreditation	-	1,082	(1,082)	-
	83,643	34,410	(100,993)	17,060

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

**17 Analysis of net assets between funds**

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
Fund balances at 30 September 2021 are represented by:				
Current assets/(liabilities)	660,472	17,060	677,532	473,087
	<u>660,472</u>	<u>17,060</u>	<u>677,532</u>	<u>473,087</u>

**18 Related party transactions**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2021 £	2020 £
Aggregate compensation	<u>63,233</u>	<u>59,192</u>